The global AI-based Embryo Grading Software market size is predicted to grow from US$ 37.3 million in 2025 to US$ 49.2 million in 2031; it is expected to grow at a CAGR of 4.7% from 2025 to 2031.
Embryo Grading Software is a specialized digital tool used in in vitro fertilization (IVF) to assess embryo quality. It automates embryo scoring, ranking, and selection based on morphological and developmental criteria, reducing subjectivity and improving implantation success rates. Many modern systems use AI, deep learning, and time-lapse imaging to enhance accuracy. AI is transforming Embryo Grading Software by enhancing accuracy, efficiency, and objectivity in selecting the best embryos for in vitro fertilization (IVF). Traditional embryo grading relies on manual evaluation by embryologists, but AI-powered systems use deep learning and computer vision to analyze embryos with greater precision.
Segmentation by Type:
- Web-based
- Cloud-based
Segmentation by Application:
- Hospital
- Clinic
- Other
Market by Region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
Company's Coverage:
- Vitrolife
- Genea BIOMEDX
- MIM Fertility
- Alife Health
- Fairtility
- ASTEC CO., Ltd
- Care Fertility
- Cycle Clarity
- KritiKal Solutions
- ImVitro
Key Questions Addressed in this Report:
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market